SEC Filing Summary: Trovagene, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on November 15, 2012, reporting events as of November 14, 2012. The filing serves to announce the company's financial results for the third quarter ended September 30, 2012. The registrant is a Delaware corporation headquartered in San Diego, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the issuance of a press release containing the third-quarter results.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (Press Release dated November 14, 2012).
- Confirm the company name discrepancy: The request metadata lists "Cardiff Oncology, Inc.," but the filing is for "Trovagene, Inc."
- Review the full press release for any operational updates or clinical trial milestones not summarized in this 8-K.